Dissecting the genetic complexity of myalgic encephalomyelitis/chronic fatigue syndrome via deep learning-powered genome analysis.
Zhang, Sai, Jahanbani, Fereshteh, Chander, Varuna et al. · medRxiv : the preprint server for health sciences · 2025 · DOI
Quick Summary
Researchers used advanced artificial intelligence to analyze the genes of ME/CFS patients and discovered 115 genes that may contribute to the disease. They found that people with ME/CFS have lower levels of these risk genes active in their immune cells and nervous system. This genetic analysis could eventually help doctors diagnose ME/CFS more accurately and identify new treatment targets.
Why It Matters
This research provides the first comprehensive genetic map of ME/CFS using cutting-edge AI analysis, potentially enabling earlier diagnosis and revealing new biological pathways for treatment development. Understanding which genes and immune cells are disrupted in ME/CFS could accelerate the search for effective therapies for a disease that currently has no cure.
Observed Findings
- Identification of 115 ME/CFS-risk genes that show significant intolerance to loss-of-function mutations.
- Reduced expression of these risk genes in patient blood plasma proteins and T cell transcriptomes, particularly in cytotoxic CD4 T cells.
- Functional involvement of identified genes across central nervous system and immune cell tissues.
- Genetic overlap between ME/CFS and depression, and between ME/CFS and long COVID-19.
- Successful development of HEAL2 deep learning model with predictive value for ME/CFS based on rare genetic variants.
Inferred Conclusions
- ME/CFS has a measurable genetic basis involving immune dysfunction and central nervous system gene expression abnormalities.
- The 115 identified risk genes represent candidate targets for therapeutic intervention in ME/CFS.
- Genetic similarities between ME/CFS, depression, and long COVID-19 suggest shared biological mechanisms across these conditions.
- Deep learning approaches can effectively identify rare genetic variants relevant to complex diseases and may serve as a diagnostic tool.
Remaining Questions
- Do the identified genetic variants have a causal relationship with ME/CFS, or are they merely associated with disease risk?
- Which of the 115 genes would be most promising as therapeutic targets, and would modifying their expression improve patient symptoms?
- Why are these particular immune cells (cytotoxic CD4 T cells) specifically affected, and what initiates this dysfunction?
- Can the HEAL2 model be validated in independent patient cohorts with sufficient sensitivity and specificity for clinical diagnostic use?
What This Study Does Not Prove
This study does not prove that these genetic variants directly cause ME/CFS, only that they are statistically associated with the disease. The findings are correlational rather than causal, and the study does not demonstrate that the identified genes would be effective drug targets or that correcting their expression would improve patient outcomes. External validation of the HEAL2 model's diagnostic accuracy in independent patient populations is still needed.
Topics
Tags
Metadata
- DOI
- 10.1101/2025.04.15.25325899
- PMID
- 40321247
- Review status
- Editor reviewed
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 7 April 2026